Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated

• Status: Completed
• Trial end date: 2012-02-14
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of bimatoprost/timolol fixed combination (GANfort®) versus latanoprost (Xalatan®) in patients with open-angle glaucoma who have never been previously treated and are at high risk for progression.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Latanoprost; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol

Criteria

Inclusion Criteria:

• Diagnosis of primary open-angle glaucoma that has never been treated

• Visual Acuity 20/60 or better in each eye

Exclusion Criteria:

• Eye surgery within 3 months

• Any refractive eye surgery

• Contraindication to beta-adrenoceptor antagonist therapy (eg, chronic obstructive pulmonary disease [COPD], bronchial asthma, sinus bradycardia, heart block, history of severe myocardial infarction [heart attack])

• Eye inflammation or eye infection within 3 months

• Eye trauma within 6 months

• Oral, injectable, or topical ophthalmic steroids within 21 days or anticipated use during study